Seoul – September 26, 2026 -- MAYPHARM has announced the upcoming launch of HYALMASS AQUATOX, a new aesthetic formulation combining five high-interest active ingredients into a single product for the global cosmeceutical market.
MAYPHARM combines five actives into one formulation to meet multifunctional demand
The new product integrates PDRN, Exosomes, Botulinum Peptide, GHK-Cu, and Succinic Acid in one advanced skin solution. Botulinum Peptide is designed to support a smoother skin appearance, while GHK-Cu is studied for skin conditioning and regeneration. Succinic Acid is positioned for antioxidant activity, PDRN for skin regeneration and recovery, and Exosomes for advanced rejuvenation approaches.
Launch builds on international interest in HYALMASS AQUA EXOSOME
MAYPHARM said the AQUATOX launch follows growing global demand for its existing HYALMASS AQUA EXOSOME product, extending the company's portfolio in the international aesthetic market.
MAYPHARM flags rising market imitation as ingredient concepts gain traction
The company noted an increase in products adopting similar ingredient combinations, visual identities, and market positioning as demand for advanced skin rejuvenation grows. MAYPHARM is urging distributors, aesthetic professionals, and customers to verify the original manufacturer, authorized supply channel, packaging, and official product information before purchasing HYALMASS products.
HYALMASS AQUATOX is described as "Coming Soon," with MAYPHARM positioning the multi-active formula as a new direction within its broader HYALMASS portfolio.